Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28121140 | 0.87 | ALDH1A1 (0.42) | DPP4ALDH1A1TSHRVCAM1TDP1 | |
| SCHEMBL30572452 | 0.87 | TDP1 (0.49) | DPP4ALDH1A1KDM4ETSHRVCAM1 | |
| SCHEMBL3423996 | 0.87 | TDP1 (0.49) | DPP4ALDH1A1KDM4ETSHRVCAM1 | |
| SCHEMBL28121145 | 0.85 | ALDH1A1 (0.41) | DPP4ALDH1A1TSHRVCAM1TDP1 | |
| SCHEMBL28121666 | 0.85 | ALDH1A1 (0.41) | DPP4ALDH1A1TSHRVCAM1TDP1 | |
| SCHEMBL28121147 | 0.85 | ALDH1A1 (0.41) | DPP4ALDH1A1TSHRVCAM1TDP1 | |
| SCHEMBL14278539 | 0.85 | DPP4 (0.40) | DPP4ALDH1A1HSD17B10KDM4ETSHR | |
| SCHEMBL1477313 | 0.82 | ALDH1A1 (0.54) | DPP4ALDH1A1HSD17B10TSHRVCAM1 | |
| SCHEMBL11796174 | 0.81 | KDM4E (0.58) | ALDH1A1HSD17B10KDM4ETDP1L3MBTL1 | |
| SCHEMBL6534956 | 0.80 | VCAM1 (0.46) | ALDH1A1KDM4ETSHRVCAM1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2008030112-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
| EP-0750620-A4 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0750620-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO. INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5496816-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO., INC. (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995025108-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DPP4 4740/4885ALDH1A1 3869/4885HSD17B10 3514/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DPP4 4740/4885ALDH1A1 3869/4885HSD17B10 3514/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | DPP4 4740/4885ALDH1A1 3869/4885HSD17B10 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.